|Fortified Flax Hulls (with Broccoli Sprouts)|
|Flax Hulls - Metals Analysis|
|Breast Cancer - reports and trials|
|Testimonies from producer|
|New Therapies for Psoriasis|
|HRT - a significant breast cancer risk|
|Importance of fibre in diet|
|Antibiotics may increase chances of Breast Cancer|
|ASA may cut breast cancer risk: study|
|Milk may lower colon cancer risk|
|Study cast doubt on soy as menopause aid|
|Warning over HRT long-term use|
|Study shows Lignans help with hair loss|
|The First Steps to a Strong Immune System|
|Sulforaphane effective against H. Pylori|
|Sulforaphane - could fight Leukemia, cancers||
New Therapies for Psoriasis
Associated Press - reported in C-Health News
November 4, 2003
It's a new era for patients covered in the itchy, scaly skin disease psoriasis. After years with few good treatments,
doctors finally have a handful of therapies that promise to help control the incurable condition with fewer bad side effects.
What changed? Scientists learned that psoriasis isn't just a skin-deep disorder but a dysfunction of
the immune system,
so the new therapies target the real culprit (see below).
"Five to six years ago, I was telling my patients it was the wasteland," says Dr. Craig Leonardi of St. Louis University Medical School, who participated
in studies of the new treatments. "Now there's this huge explosion of amazing drugs coming forward."
The new options don't help everyone, cautions Dr. Michael Tharp, dermatology chief at Chicago's Rush University Medical Center. And they're very expensive,
costing $10,000 a year or more.
But, "it's a great first step," Tharp says. "Now we've got very directed molecules and know where they work and how they work. ... I hope it is just the beginning."
Two unique psoriasis shots, Amevive and Raptiva, recently won Food and Drug Administration approval. Two drugs already sold to treat other
conditions -- Enbrel and Remicade -- are used against psoriasis, too. A list of other potential treatments is under study.
The four newest options haven't yet been compared to each other, but because each works somewhat differently, specialists expect hard-to-treat patients to find some relief
among the bunch.
Some 4.5 million Americans have psoriasis. Of those, 1.5 million suffer moderate to severe symptoms -- their skin covered in red or white scaly patches that burn and itch. It's
triggered when certain immune system cells, called memory effector T cells, run amok, causing skin cells to multiply faster than normal and become
It can be life-altering.
"I wouldn't wear anything but long-legged pants and long-sleeved shirts because I got so tired of people asking me questions," says Lyle Newcomb, 60, of Milwaukie, Ore., who
tried every treatment without success. "You don't allow yourself to get real close to anybody because you don't know how they're going to accept it."
Then Newcomb entered a study of Raptiva. "I had never been clear of psoriasis in my life, but I was totally clear in three weeks," and, two years later, weekly shots keep symptoms
Ointments and light therapy -- ultraviolet beams, sometimes with light-sensitizing drugs, a few times a week -- are effective for milder psoriasis.
Until now, severely hit patients had two powerful options, each with serious side effects. The immune suppressor cyclosporine,
commonly used to prevent rejection of transplanted organs, can destroy kidneys. Inflammation-suppressing methotrexate, also used
for cancer and rheumatoid arthritis, can cause liver damage.
The new biologically engineered treatments promise more targeted therapy without those risks:
--Amevive and Raptiva interfere with the harmful T cells, dramatically clearing psoriasis lesions in 20 percent to 40 percent of patients.
Amevive causes those T cells to die, explaining why some people's symptoms don't return for months after a three-month course of weekly shots. About 3,500 patients
have begun Amevive since FDA approval in January, says maker Biogen Inc. The intramuscular shots are given in a doctor's office.
In contrast, Raptiva keeps harmful immune cells from getting into and inflaming skin, so patients must take it indefinitely. Sales will begin by Thanksgiving, say
makers Genentech Inc. and Xoma Ltd. Patients give themselves weekly under-the-skin shots.
That difference means more than convenience; some insurance pays for in-office therapy but not at-home drugs.
--Instead of targeting T cells, Enbrel and Remicade inhibit a protein, TNF, that's crucial to inflammation. FDA-approved for certain types of arthritis, some doctors
already use the drugs for psoriasis' skin lesions. The FDA now is evaluating Enbrel injections for that use; a final-stage study of intravenous Remicade is about to begin.
Specialists call the four new treatments largely safe but acknowledge that even mildly tinkering with the immune system for years might spur infections or cancer. "We're crossing our fingers," Tharp says.
That plus their huge cost means the new drugs are reserved for the worst patients. For less severe psoriasis sufferers, "we're back in the stone ages," Tharp says, urging companies to study better options for
Support Psoriasis treatment by boosting your immune system with a nutritional therapy comprising of
LB17 "live" probiotic
and Natural Concentrated Flax Hulls
See below for a sample of Fortified Flax Hulls (1st pic) and Flax Hulls (2nd pic)
Each jar contains 180gm of fortified flax hulls or 150gm of flax hulls
The above information is provided for general
educational purposes only. It is not intended to replace competent
health care advice received from a knowledgeable healthcare professional.
You are urged to seek healthcare advice for the treatment of any
illness or disease.
Health Canada and the FDA (USA) have not evaluated these
statements. This product is not intended to diagnose, treat, cure, or prevent